TMEFF2 and prostate carcinoma: The injection of TMEFF2 mAb on its own did not have any effect on xenografts, and there was neither differences in proliferation reported in the tomoregulin-stable PC3 prostate cancer cells nor any difference observed in the proliferation of LNCap or PC3 cells when the extracellular domain of tomoregulin was added to the cell cultures.